The IL-23 inhibitor from AbbVie indicated for the treatment of adults with
active psoriatic arthritis (PsA) and for moderate to severe plaque psoriasis (Ps)
in adults who are candidates for systemic therapy or phototherapy.1

Learn more about AbbVie’s response to COVID-19

1 injection, 4 times a year

after week 0 and 4 injections1

Reliable 3-MONTH DOSING1

ADMINISTERED BY A SINGLE 150 mg/mL SUBCUTANEOUS INJECTION AT:

Initiation

SKYRIZI® 150 mg/mL single-dose pen.

WEEK 0

SKYRIZI® 150 mg/mL single-dose pen.

WEEK 4

Month 3

SKYRIZI® 150 mg/mL single-dose pen.

WEEK 16

Month 6

SKYRIZI® 150 mg/mL single-dose pen.

WEEK 28

Month 9

SKYRIZI® 150 mg/mL single-dose pen.

WEEK 40

Month 12

SKYRIZI® 150 mg/mL single-dose pen.

WEEK 52

SKYRIZI® 150 mg/mL single-dose pen and 150 mg/mL single-dose prefilled syringe.

FLEXIBILITY to choose
between the 150 mg/mL single-dose pen or 150 mg/mL single-dose prefilled syringe1

3-MONTH DOSING1

after 2 initiation doses
at Weeks 0 and 4 (150 mg/dose)

2 administration options1

for in-office or at-home administration after proper training

1 DOSAGE
FOR ALL PATIENTS1

regardless of baseline weight,
disease severity, or prior treatment

The Skyrizi Pen was awarded an Ease of Use seal from the Arthritis Foundation after being tested by patients with psoriatic arthritis.2

ADMINISTRATION Considerations1

  • SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI according to the Instructions for Use
  • SKYRIZI may be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs) for patients with active PsA
SKYRIZI® dosing card PDF.

Download OR EMAIL
DOSING CARD

Download or Email

INJECTION SUPPORT VIDEOS

150 mg/mL
SKYRIZI PEN

After receiving proper training, your SKYRIZI patients who choose to self-inject can reference this video for additional injection support.

150 mg/mL
PREFILLED SYRINGE

After receiving proper training, your SKYRIZI patients who choose to self-inject can reference this video for additional injection support.


ACR20/50/70 RESPONSE RATES

In patients with PsA at Week 24 and 1 year1,3,4

Primary endpoint ACR20 at 24 weeks

EXCEPTIONAL PATIENT ACCESS & SUPPORT

For your patients with PsA